A method for reproducible measurements of serum BDNF: Comparison of the performance of six commercial assays

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Polacchini, Alessio ^a   Metelli, Giuliana ^a   Francavilla, Ruggiero ^a   Baj, Gabriele ^a   Florean, Marina ^b   Mascaretti, Luca Giovanni ^b   Tongiorgi, Enrico ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; DIAGNOSTIC KIT;

ADULT; AGED; BLOOD; DIAGNOSTIC KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MIDDLE AGED; NORMAL HUMAN; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STANDARDS;

ADULT; AGED; BIOMARKERS; BRAIN-DERIVED NEUROTROPHIC FACTOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84949672050     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep17989     Document Type: Article

References (59)

1. van Beveren, N. J. & Hoogendijk, W. J. Clinical utility of serum biomarkers for major psychiatric disorders. Int Rev Neurobiol 101, 351-374 (2011).
2. Lakhan, S. E., Vieira K. & Hamlat, E. Biomarkers in psychiatry: drawbacks and potential for misuse. Int Arch Med 3, 1 (2010).
3. Poste G. Bring on the biomarkers. Nature 469, 156-157 (2011).
4. Drucker, E. & Krapfenbauer, K. Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine. EPMA J 4, 7 (2013).
5. Pruunsild, P. et al. Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters. Genomics 90, 397-406 (2007).
6. Schinder, A. F. & Poo, M. The neurotrophin hypothesis for synaptic plasticity. Trends Neurosci 23, 639-645 (2000).
7. Huang, E. J. & Reichardt, L. F. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 24, 677-736 (2001).
8. Carlino, D. et al. Low serum truncated-BDNF isoform correlates with higher cognitive impairment in schizophrenia. J Psychiatr Res 45, 273-279 (2011).
9. Garcia, K. L. et al. Altered balance of proteolytic isoforms of pro-brain-derived neurotrophic factor in autism. J Neuropathol Exp Neurol 71, 289-297 (2012).
10. Carlino, D., De Vanna M. & Tongiorgi, E. Is altered BDNF biosynthesis a general feature in patients with cognitive dysfunctions? Neuroscientist 19, 345-353 (2013).
11. Sen, S., Duman, R. & Sanacora, G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: metaanalyses and implications. Biol Psychiatry 64, 527-532 (2008).
12. Molendijk, M. L. et al. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N = 9484). Mol Psychiatry 19, 791-800 (2014).
13. Green, M. J. et al. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol Psychiatry 16, 960-972 (2011).
14. Fernandes, B. S. et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res 45, 995-1004 (2011).
15. Hashimoto, K. et al. Reduced serum levels of brain-derived neurotrophic factor in adult male patients with autism. Prog Neuropsychopharmacol Biol Psychiatry 30, 1529-1531 (2006).
16. Katoh-Semba, R. et al. Age-related changes in BDNF protein levels in human serum: differences between autism cases and normal controls. Int J Dev Neurosci 25, 367-372 (2007).
17. Archer, T. Influence of physical exercise on traumatic brain injury deficits: scaffolding effect. Neurotox Res 21, 418-434 (2012).
18. Bocchio-Chiavetto, L. et al. et al. Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J Biol Psychiatry 11, 763-773 (2010).
19. Krogh, J. et al. The effect of exercise on hippocampal volume and neurotrophines in patients with major depression - A randomized clinical trial. J Affect Disord 165, 24-30 (2014).
20. Vinogradov, S. et al. Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia? Biol Psychiatry 66, 549-553 (2009).
21. El-Tamawy, M. S. et al. Aerobic exercises enhance cognitive functions and brain derived neurotrophic factor in ischemic stroke patients. NeuroRehabilitation 34, 209-213 (2014).
22. Lahera, G. et al. Mindfulness-based cognitive therapy versus psychoeducational intervention in bipolar outpatients with sub-threshold depressive symptoms: a randomized controlled trial. BMC Psychiatry 14, 215 (2014).
23. Bus, B. A. et al. Determinants of serum brain-derived neurotrophic factor. Psychoneuroendocrinology 36, 228-239 (2011).
24. El-Gharbawy, A. H. et al. Serum brain-derived neurotrophic factor concentrations in lean and overweight children and adolescents. J Clin Endocrinol Metab 91, 3548-3552 (2006).
25. Piccinni, A. et al. Diurnal variation of plasma brain-derived neurotrophic factor (BDNF) in humans: an analysis of sex differences. Chronobiol Int 25, 819-826 (2008).
26. Bus, B. A. et al. Serum brain-derived neurotrophic factor: determinants and relationship with depressive symptoms in a community population of middle-aged and elderly people. World J Biol Psychiatry 13, 39-47 (2012).
27. Giese, M. et al. Fast BDNF serum level increase and diurnal BDNF oscillations are associated with therapeutic response after partial sleep deprivation. J Psychiatr Res 59, 1-7 (2014).
28. Begliuomini, S. et al. Plasma brain-derived neurotrophic factor daily variations in men: correlation with cortisol circadian rhythm. J Endocrinol 197, 429-435 (2008).
29. Choi, S. W., Bhang S. & Ahn, J. H. Diurnal variation and gender differences of plasma brain-derived neurotrophic factor in healthy human subjects. Psychiatry Res 186, 427-430 (2011).
30. Elfving, B., Plougmann, P. H. & Wegener, G. Detection of brain-derived neurotrophic factor (BDNF) in rat blood and brain preparations using ELISA: pitfalls and solutions. J Neurosci Methods 187, 73-77 (2010).
31. Maffioletti, E., Zanardini, R., Gennarelli, M. & Bocchio-Chiavetto, L. Influence of clotting duration on brain-derived neurotrophic factor (BDNF) dosage in serum. Biotechniques 57, 111-114 (2014).
32. Trajkovska, V. et al. Measurements of brain-derived neurotrophic factor: methodological aspects and demographical data. Brain Res Bull 73, 143-149 (2007).
33. Radka, S. F., Holst, P. A., Fritsche, M. & Altar, C. A. Presence of brain-derived neurotrophic factor in brain and human and rat but not mouse serum detected by a sensitive and specific immunoassay. Brain Res 709, 122-301 (1996).
34. Fujimura, H. et al. Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb Haemost 87, 728-734 (2002).
35. Karege, F. et al. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry 57, 1068-1072 (2005).
36. Lommatzsch, M. et al. Brain-derived neurotrophic factor in platelets and airflow limitation in asthma. Am J Respir Crit Care Med 171, 115-120 (2005).
37. Lommatzsch, M. et al. Abundant production of brain-derived neurotrophic factor by adult visceral epithelia. Implications for paracrine and target-derived Neurotrophic functions. Am J Pathol 155, 1183-1193 (1999).
38. Nakahashi, T. et al. Vascular endothelial cells synthesize and secrete brain-derived neurotrophic factor. FEBS Lett 470, 113-117 (2000).
39. Kishino, A. et al. Analysis of effects and pharmacokinetics of subcutaneously administered BDNF. Neuroreport 12, 1067-1072 (2001).
40. Poduslo, J. F. & Curran, G. L. Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Res Mol Brain Res 36, 280-286 (1996).
41. Drakopoulos, P. et al. Diurnal Variation of Plasma Brain-Derived Neurotrophic Factor Levels in Women with Functional Hypothalamic Amenorrhea. Neuroendocrinology 101, 256-262 (2015).
42. Zuccato, C. et al. Brain-derived neurotrophic factor in patients with Huntington's disease. PLoS One 6, e22966 (2011).
43. Yoshida, T. et al. Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. PLoS One 7, e42676 (2012).
44. Baj, G., Carlino, D., Gardossi, L. & Tongiorgi, E. Toward a unified biological hypothesis for the BDNF Val66Met-associated memory deficits in humans: a model of impaired dendritic mRNA trafficking. Front Neurosci 7, 188 (2013).
45. Riffault, B. et al. Pro-brain-derived neurotrophic factor inhibits GABAergic neurotransmission by activating endocytosis and repression of GABAA receptors. J Neurosci 34, 13516-13534 (2014).
46. Monteleone, P. et al. Opposite changes in the serum brain-derived neurotrophic factor in anorexia nervosa and obesity. Psychosom Med 66, 744-748 (2004).
47. Ziegenhorn, A. A. et al. Serum neurotrophins - A study on the time course and influencing factors in a large old age sample. Neurobiol Aging 28, 1436-1445 (2007).
48. Elfving, B. et al. Depression, the Val66Met polymorphism, age, and gender influence the serum BDNF level. J Psychiatr Res 46, 1118-1125 (2012).
49. Lang, U. E., Hellweg, R. & Gallinat, J. BDNF serum concentrations in healthy volunteers are associated with depression-related personality traits. Neuropsychopharmacology 29, 795-798 (2004).
50. Suwa, M. et al. Serum brain-derived neurotrophic factor level is increased and associated with obesity in newly diagnosed female patients with type 2 diabetes mellitus. Metabolism 55, 852-857 (2006).
51. Suriyaprom, K., Tungtrongchitr, R., Thawnashom, K. & Pimainog, Y. BDNF Val66Met polymorphism and serum concentrations of BDNF with smoking in Thai males. Genet Mol Res 12, 4925-4933 (2013).
52. Jamal, M. et al. Association of Smoking, Nicotine Dependence, and BDNF Val66Met Polymorphism with BDNF Concentrations in Serum. Nicotine Tob Res, (2014).
53. Yoshimura, R. et al. The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients. Prog Neuropsychopharmacol Biol Psychiatry 35, 1022-1025 (2011).
54. Katsuki, A. et al. Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD). CNS Spectr 17, 155-163 (2012).
55. Grande, I. et al. Val66Met polymorphism and serum brain-derived neurotrophic factor in bipolar disorder: an open-label trial. Acta Psychiatr Scand 129, 393-400 (2014).
56. Terracciano, A. et al. Genetics of serum BDNF: meta-analysis of the Val66Met and genome-wide association study. World J Biol Psychiatry 14, 583-589 (2013).
57. Lotrich, F. E., Albusaysi, S. & Ferrell, R. E. Brain-derived neurotrophic factor serum levels and genotype: association with depression during interferon-alpha treatment. Neuropsychopharmacology 38, 985-995 (2013).
58. Cerasa, A. et al. The effects of BDNF Val66Met polymorphism on brain function in controls and patients with multiple sclerosis: an imaging genetic study. Behav Brain Res 207, 377-386 (2010).
59. Kapur, S., Phillips, A. G. & Insel T. R. Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? Mol Psychiatry 17, 1174-1179 (2012).